| Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models JS Owen, J Fiedler-Kelly John Wiley & Sons, 2014 | 188 | 2014 |
| Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma JS Owen, M Melhem, JA Passarell, D D’Andrea, M Darwish, B Kahl Cancer chemotherapy and pharmacology 66 (6), 1039-1049, 2010 | 83 | 2010 |
| Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes JK Mukonzo, JS Owen, J Ogwal-Okeng, RB Kuteesa, S Nanzigu, ... PLoS One 9 (1), e86919, 2014 | 80 | 2014 |
| Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects SM Bhavnani, JS Owen, JS Loutit, SB Porter, PG Ambrose Diagnostic microbiology and infectious disease 50 (2), 95-102, 2004 | 76 | 2004 |
| Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections SA Van Wart, JS Owen, EA Ludwig, AK Meagher, JM Korth-Bradley, ... Antimicrobial agents and chemotherapy 50 (11), 3701-3707, 2006 | 75 | 2006 |
| Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia SM Bhavnani, JA Passarell, JS Owen, JS Loutit, SB Porter, PG Ambrose Antimicrobial agents and chemotherapy 50 (3), 994-1000, 2006 | 75 | 2006 |
| Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis®) in cancer patients JJ Perez-Ruixo, P Zannikos, S Hirankam, K Stuyckens, EA Ludwig, ... Clinical pharmacokinetics 46 (10), 867-884, 2007 | 54 | 2007 |
| Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis PG Ambrose, JB Anon, JS Owen, S Van Wart, ME McPhee, SM Bhavnani, ... Clinical infectious diseases 38 (11), 1513-1520, 2004 | 42 | 2004 |
| Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects AB Pai, JC Nielsen, A Kausz, P Miller, JS Owen Clinical Pharmacology & Therapeutics 88 (2), 237-242, 2010 | 35 | 2010 |
| Population pharmacokinetics of tigecycline in healthy volunteers SA Van Wart, BB Cirincione, EA Ludwig, AK Meagher, JM Korth‐Bradley, ... The Journal of Clinical Pharmacology 47 (6), 727-737, 2007 | 35 | 2007 |
| Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment GJ Fetterly, JS Owen, K Stuyckens, JA Passarell, P Zannikos, ... Cancer chemotherapy and pharmacology 62 (1), 135-147, 2008 | 34 | 2008 |
| Challenges in the transition to model-based development TH Grasela, J Fiedler-Kelly, CA Walawander, JS Owen, BB Cirincione, ... The AAPS journal 7 (2), E488-E495, 2005 | 31 | 2005 |
| Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti–tuberculosis therapy KR Bisaso, JS Owen, FW Ojara, PM Namuwenge, A Mugisha, ... In silico pharmacology 2 (1), 1-8, 2014 | 24 | 2014 |
| CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population JK Mukonzo, RK Bisaso, J Ogwal-Okeng, LL Gustafsson, JS Owen, ... Pharmacogenomics 17 (6), 603-613, 2016 | 19 | 2016 |
| Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin lymphoma JS Owen, M Melhem, D D’Andrea, M Darwish Pharmacol Ther 83 (suppl 1), S54, 2008 | 19 | 2008 |
| Dose–response and cardiopulmonary side effects of the novel neuromuscular-blocking drug CW002 in man PM Heerdt, H Sunaga, JS Owen, MT Murrell, JK Malhotra, D Godfrey, ... Anesthesiology 125 (6), 1136-1143, 2016 | 18 | 2016 |
| Long‐Term Effect of Rifampicin‐Based Anti‐TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8‐Hydroxy‐Efavirenz in Ethiopian Patients A Habtewold, E Aklillu, E Makonnen, W Amogne, G Yimer, G Aderaye, ... The Journal of Clinical Pharmacology 56 (12), 1538-1549, 2016 | 15 | 2016 |
| Development and validation of a UPLC method for rapid and simultaneous analysis of proton pump inhibitors RT Addo, K Davis, R Ubale, JS Owen, EB Watkins AAPS PharmSciTech 16 (1), 30-34, 2015 | 14 | 2015 |
| Noncompartmental pharmacokinetics of tigecycline in patients with complicated skin and skin structure infections JS Owen, IM Darling, SM Troy, BB Cirincione Programs and Abstracts of the Forty-fourth Interscience Conference on …, 2004 | 14 | 2004 |
| Buprenorphine implants in medical treatment of opioid addiction S Chavoustie, M Frost, O Snyder, J Owen, M Darwish, R Dammerman, ... Expert review of clinical pharmacology 10 (8), 799-807, 2017 | 13 | 2017 |
